Oncology Institute (TOIIW) Return on Equity (2020 - 2026)

Oncology Institute has reported Return on Equity for 7 years, with the latest figure at 0.03% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity rose 18.0% year-over-year to 0.03%; the trailing twelve-month figure through Mar 2026 stood at 0.03% (up 18.0% YoY), and the FY2025 full-year result was 0.1%, up 12.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.03%, down from 0.04% in the prior quarter.
• The five-year high for Return on Equity was 0.34% in Q2 2025, with the low at 0.15% in Q1 2025.
• Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.0% in 2023.
• The largest YoY upside for Return on Equity was 36 bps in 2025 against a maximum downside of 13 bps in 2025.
• Oncology Institute's Return on Equity stood at 0.0% in 2022, then sank by 106585 bps to 0.01% in 2023, then slumped by 426 bps to 0.07% in 2024, then jumped by 164 bps to 0.04% in 2025, then slumped by 37 bps to 0.03% in 2026.
• The last three Return on Equity figures came in at 0.03% (Q1 2026), 0.04% (Q4 2025), and 0.06% (Q3 2025), per Business Quant data.